Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could IVF hormones trigger aging cells in the womb and lower pregnancy chances?

NCT ID NCT06280560

Knowledge-focused Sponsor: Fundación IVI Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This study investigates whether the high hormone levels used in IVF ovarian stimulation and luteal phase support alter the endometrium, the uterine lining where an embryo implants. Researchers will compare tissue from subfertile IVF patients undergoing these hormone treatments with tissue from oocyte donors in a natural cycle. They will measure markers of endometrial receptivity and look for an abnormal buildup of senescent cells, which are aged cells that stop dividing and can disrupt tissue function. The goal is to see if these hormone protocols cause changes that reduce implantation success, and whether senolytic drugs that clear senescent cells could reverse those effects in the lab.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Controlled ovarian stimulation with FSH and HMG, followed by progesterone luteal phase support
What this could lead to
If the hypothesis holds, this could point toward adding senolytic drugs to IVF protocols to improve implantation and pregnancy rates.
What could go wrong
This is a small pilot study measuring cell markers in the lab, not pregnancy outcomes. The findings may not translate to real-world IVF success, and senolytic drugs are not yet tested in patients here.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist in 45 women undergoing IVF treatment for fertility problems and who, as indicated by their clinical practice, will be subjected to one of the following hormonal protocols (fifteen participants per group) (Natural Cycle, Controled Ovarian Stimulation + Luteal Phase Support, Hormone Replacement Therapy). Additionally, as an endometrial receptivity reference group, we will recruit a population of 15 women with proven fertility belonging to the oocyte donation program in an endometrial cycle without hormonal stimulation (natural cycle). The 60 participants will be recruited at the IVI-RMA Valencia clinic (Valencia).

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Study group (subfertile IVF patients). * Inclusion Criteria: Women aged 18-45 years, BMI ≥ 18.5- 30. * Exclusion criteria: Women presenting any uterine disease that affects the endometrial cavity, or with a thin or irregular endometrium, altered karyotypes, thrombophilias, or uncorrected systemic or endocrine diseases will be excluded. Endometrial receptivity reference group (oocyte donors). * Inclusion criteria: women aged between 18 and 35 years, BMI ≥ 18.5- 25. * Exclusion criteria: Any cases of DIU presence, hormonal contraceptives at least during the last three months, altered karyotypes, thrombophilias, or uncorrected systemic or endocrine diseases will be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial receptivity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial receptivity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IVI-RMA Valencia Clinic

    RECRUITING

    Valencia, Valencia, 46015, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.